gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NEPHHealthcareSurgical Instruments

Nephros Inc. (NEPH)

$3.25+0.31%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.25▼ 37.50% in range
Nov 4, 2025Low $2.78 · High $5.79Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Nephros closed at $3.25 on Nov 4, up 0.31%, 43.8% below its 52-week closing high. Volume of 10.4K shares was 0.20× its 20-day average (below normal).

Split-adjusted performance: +7.6% over one month, +0.9% over six months, -39.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $6.02M, up 36.2% from a year earlier, with a net margin of 19.9%.

Short interest was 15.4K shares at the Oct 15 settlement, down 39.0% from the prior report (0.2% of float, 1.0 days to cover).

Market cap$35.3M10.9M shares
Revenue · quarter$6.0M+36.2% YoY
Diluted EPS$0.11+450.0% YoY
P/E · TTM20.3×P/S 1.7×
Net margin19.9%Gross 66.9%
Dividend yieldNone
52-week range2.78 – 5.79−43.8% from high
Volume10.4K0.20× 20-day avg
Volatility · 60d72.5%Annualised
Short % of float0.2%1.0 days to cover
Net cash$4.7MCash $4.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +2.5%1M +7.6%3M −9.5%6M +0.9%YTD −33.4%1Y −39.5%3Y +101.9%5Y −57.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum54
Revenue growth90
Net margin90
Value (low P/E)70
Size27

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short15.4K−39.0% vs prior
Days to cover1.0Settled Oct 15
% of float0.2%
Short vol. 10d23.7%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NEPHNephros$3.25+0.31%+0.9%+36.2%19.9%20.3$35.3M
NSPRInspireMD$0.7810+18.71%−32.7%−0.4%−808.8%—$36.6MCompare
TELATELA Bio$0.8378+4.46%−15.4%−4.5%−58.4%—$37.8MCompare
XTNTXtant Medical Holdings$0.2960+6.47%−48.7%−35.0%−40.9%—$41.5MCompare
CVRXCVRx$1.58+14.49%−77.7%+15.6%−89.4%—$42.1MCompare
DRIODarioHealth$2.97−1.00%−62.8%−3.6%−153.1%0.0$29.1MCompare
MDAISpectral AI$1.53+2.00%−31.1%−30.4%−118.5%—$49.2MCompare
SNWVSANUWAVE Health$5.73−3.37%−64.0%−3.1%−7.0%3.4$49.3MCompare
DXRDaxor$8.91+2.44%−12.1%+2.3%−403.2%—$52.0MCompare

News about Nephros

All news →
Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ETGlobeNewswire Inc. · Jul 20, 2026▲ PositiveNephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”GlobeNewswire Inc. · Jun 18, 2026▲ PositiveNephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in WaterGlobeNewswire Inc. · Jun 16, 2026▲ PositiveNephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning ExpertiseGlobeNewswire Inc. · Apr 1, 2026▲ Positive

Quick answers

What does Nephros do?
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products.
What is NEPH's market cap?
$35.33M, based on the Nov 4 close of $3.25.
What is NEPH's P/E ratio?
20.3× trailing-twelve-month earnings of $1.74M.
Does Nephros pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NEPH is sold short?
15.4K shares, 0.2% of float, as of Oct 15, 2026.
What sector is NEPH in?
Healthcare, in the Surgical Instruments industry.

About Nephros

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

HQ: South Orange, NJ36 employeesListed Sep 21, 2004nephros.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology